XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
P
P

Pfizer

Yangiliklar

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P

Greece is unlikely victor in bank selldown race

BREAKINGVIEWS-Greece is unlikely victor in bank selldown race The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Liam Proud LONDON, Oct 3 (Reuters Breakingviews) - In 2010, it was hard to imagine the day when Greece's banking sector would be fully privatised and thriving. That was the year the government founded the Hellenic Financial Stability Fund (HFSF) to prop up ailing lenders.
C
E
M
P
U
A
A
P

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.